Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition
- PMID: 6441763
- DOI: 10.1055/s-2007-1014876
Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition
Abstract
The inhibitory effect of various doses of dopamine on serum PRL levels was assessed in both normal cycling women and patients with tumoral hyperprolactinemia before and after endogenous catecholamine synthesis inhibition by alpha-methyl-p-tyrosine, a strong and specific tyrosine-hydroxylase inhibitor. Dopamine infusion induced a significant decrease in the serum PRL levels in both normal cycling and hyperprolactinemic subjects. The mean percent inhibition of baseline PRL induced by the various dopamine infusion rates (0.1, 0.5, 1.0 and 2.0 micrograms/kg/min) was similar in regularly cycling women and in patients with tumoral hyperprolactinemia both before and after endogenous catecholamine synthesis inhibition by alpha-methyl-p-tyrosine. Alpha-methyl-p-tyrosine pretreatment significantly increased serum PRL concentrations in normal women and enhanced their responsiveness to the exogenously administered dopamine. Hyperprolactinemic patients, on the contrary, did not show any significant variation in either basal PRL release or the PRL sensitivity to dopamine infusion after endogenous catecholamine synthesis inhibition. These data indicate that reduced dopamine delivery to the adenomatous lactotroph, either due to a primary hypothalamic abnormality or to a deranged vascular pituitary arrangement, rather than a reduced PRL sensitivity to dopamine inhibition, is the main event accounting for PRL hypersecretion in women with PRL-secreting pituitary tumors.
Similar articles
-
Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?Front Endocrinol (Lausanne). 2023 Jan 12;13:1057749. doi: 10.3389/fendo.2022.1057749. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36714572 Free PMC article. Review.
-
Dopamine as a prolactin (PRL) inhibitor.Endocr Rev. 2001 Dec;22(6):724-63. doi: 10.1210/edrv.22.6.0451. Endocr Rev. 2001. PMID: 11739329 Review.
-
Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia.Horm Res. 1984;20(3):202-12. doi: 10.1159/000179997. Horm Res. 1984. PMID: 6436160
-
Catecholamines and pituitary function. I. Effects of catecholamine synthesis inhibition and subsequent catecholamine infusion on gonadotropin and prolactin serum levels in normal cycling women and in women with hyperprolactinemic amenorrhea.Horm Res. 1984;19(3):158-70. doi: 10.1159/000179883. Horm Res. 1984. PMID: 6425187
-
Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.Horm Metab Res. 1986 Jul;18(7):479-84. doi: 10.1055/s-2007-1012351. Horm Metab Res. 1986. PMID: 3091473
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical